However, Levy et al. [54] recently reported that the selective pan-AKT inhibitor GSK690693 possessed potent antiproliferative activity in 12 of 15 B-lineage ALL cell lines, including two that were BCR-ABL positive. This evidence concerns the gene BCR and acute lymphoblastic leukemia.